ODS Deputy Director Anne Trontell will embark on a year-long FDA-sponsored detail beginning in mid-January as a senior advisor in pharmaceutical outcomes research for the Agency for Healthcare Research & Quality. The move will help to improve understanding of the health outcomes of marketed drugs, FDA says, noting the collaboration is part of an effort to foster research partnerships on drug effectiveness and safety. Trontell will promote collaborative research between FDA, AHRQ, CMS, and professional and academic institutions. Office of Pharmacoepidemiology and Statistical Science Deputy Director Jonca Bull will serve as acting ODS deputy director...
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.